Remdesivir accelerated the stup covid-19, uke study. Mortality dreamed by 31%

Lk remdesivir, which is hoped for the love of covid-19, is the first rush in clinical trials. Compared with placebo, it had better results. In patients with tkm during covid-19, remdesivir recovered rapidly. Tm o tetin thus increased the patient’s attention to the peit.

The US government’s state of nationalism for allergies and infectious diseases has announced the above results from a clinical trial. He published the preliminary results of the ACTT clinical study, which aims to investigate the action of the drug remdesivir in the fight against the tissue of covid-19.

Experiment

Experimentln lk Remdesivir

The study included 1,063 patients, one of whom received an experimental remdesivir from Gilead Sciences during their hospital stay, and another received an innocent substance (placebo). Because it was a double-blind study, neither the test nor the placebo gave the patient a dose. Such a check was only possible where there is no known effect or, if it existed, the experimental preparation would have to be compared with n.

Remdesivir (v

Remdesivir is a dead nron on vrobu

So far, these are the first preliminary results, not a peer-reviewed study. Pesto is a cause for cautious optimism. And for Gilead, this is an important result, because a week ago it caused a great response by mistake, first of all, about the fact that one of the clinical trials failed. And just as the stock markets reacted to the backsliding of the remdesivir at the time, not only the shares of Gilead, but also the stock markets in the USA and Asia in general reacted to the rush. This shows that remdesivir is much more like a potential tool against a pandemic.

Encouraging and statistically significant results

What exactly do we strike from the strings first? All the relevant results that have been published so far from the APTT study are presented in a single paragraph.

  • esky
  • Originl

Pediatric results indicate that patients who received remdesivir recovered 31% faster than patients who received placebo (p

Preliminary results indicate that patients who received remdesivir had a 31% faster time to recovery than those who received placebo (p

The statistical significance of such results is high. Of course, this is only one of a series of clinical trials (another study published in the Lancet, on the other hand, did not record anything else), but these results are still promising.

At the same time, it is obvious that remsedivir is not big. He didn’t take it all and didn’t pour it all out. He was blamed only on people who had the course of the disease covid-19 tk, and dreamed their mortality by 3.6 percentage points, ie dark aunt. For hypothetical thousands of people in a state of the art, this would mean 36 life-saving lives. That’s not enough. But is it enough to treat covid-19 as a new threat?

Of course, it’s soon to be a big mess. Remdesivir as well as other potential therapies need to be tested in different contexts, doors and procedures. So far, there is a slight slowdown in the disease: It does not look 100%, but it is important to show that I am working against the virus, commented Anthony Fauci, director of the National State for Allergies and Infectious Diseases, an adviser to the US president.

esk biochemist Tom Cihl

He gave tests to show how much remdesivir developed under the leadership of the Czech scientist Tom Brick changed the dynamics of the fight against the new coronavirus.

Where did the remdesivir come from?

There are currently at least six clinical trials of remdesivir. Few tests were performed, but they did not prove much or less about the activity of the drug. For the first time, 12 patients who received lk ​​in the United States between January 25 and the 5th of this year came from a very small sample. (The first patient, who was only a remdesivir, went to the hospital on January 19.) Seven patients were hospitalized, several of whom even had a relatively high course of illness. None of them died. However, because it was missing compared to other drugs, the authors of the work, despite these results, are not able to assess the activity and safety of the product.

That April, a paper was published in the New England Journal by Medicine (NEJM) describing the results of about 60 patients who received the compassionate use program. Again, this was not a clinical study that would simply be comparable to another treatment, and the results are therefore inconclusive.

it was a group of very sick patients in an outpatient condition who qualified for the program for the first time (also because they were pregnant and could have lost two lives). The only at least somewhat relevant comparison is between the different groups of these patients. Remdesivir did not get far from all the patients who could qualify for the program. For example, because he was not available during the Wuhan outbreak.

The authors of the work in the BEST bag point out that the group of patients on remdesivirus among the similar cohorts belonged to the lowest number of indicators. About 18 days (which is medin) from the company, the mortality in the groups was 13 percent. Mortality ranged from 17 to 78 percent in the high voltage patient groups. In a clinical study intensively investigating the combination of lopinavirritonavir in patients with tkm, mortality was 22 percent. But as we died, the patients in the individual studies could not be compared directly.

Let us add that patients with a really difficult course are not particularly suitable for remdesivir and other antiviral drugs. Based on tests, it should be noted that patients with a mild course of infection may otherwise be less observable. If the other were the same in humans as in the experimental invitations, which is far from certain, at the very beginning of the infection, the preparation could slow down the multiplication of the virus. And so sharply that the disease should be easy to drive in that percentage of cases not usually.

Remdesivir was originally supposed to fight Ebola

The preparation did not have any symptoms, only the virus should complicate its multiplication in the body. Viruses can’t do it alone, they need a host beech to trick them into producing a new generation of virus. Remdesivir and similar preparations (more precisely, the so-called nucleotide analogues) are very simplified, but they serve as fake building blocks suitable for the construction of other copies of the virus. In fact, they contain an instruction to complete the construction, and the multiplication of the virus therefore stops the presence of the product. So, at least in some cases, in practice, of course, the procedure may not work. For example, because the virus mutates and does not use falen dly.

The product, which is administered in the form of an infusion, should be used against a relatively wide range of viruses, while its use has not been officially approved for use. In 2019, he was tested in the Democratic Republic of Congo against the Ebola virus. Remdesivir, however, did not do well and began to let the patients ride before the end of the test. Jin ltky have shown innj.

admin000biet

The scientists helped to find the energy bond that shows how the metal is formed
  • idnes Science

The scientists helped to find the energy bond that shows how the metal is formed

One step back  The authors of a large study on hydroxychloroquine withdrew their work
  • idnes Science

One step back The authors of a large study on hydroxychloroquine withdrew their work

Hydroxychloroquine code, a large analysis claimed.  Only until it was downloaded
  • idnes Science

Hydroxychloroquine code, a large analysis claimed. Only until it was downloaded

Both the US and Europe lost coronavirus in January.  Then piel a second time
  • idnes Science

Both the US and Europe lost coronavirus in January. Then piel a second time

No speed test.  In esku b study bunn immunity against covid-19
  • idnes Science

No speed test. In esku b study bunn immunity against covid-19

Mete mt svj nzor, not sv fakta.  When you’re a greyhound on vdce, so podn
  • idnes Science

Mete mt svj nzor, not sv fakta. When you’re a greyhound on vdce, so podn

Leave a Reply Cancel reply